A Case of Fibrolamellar Hepatocellular Carcinoma at the High Specialty Hospital of Veracruz, Mexico

Main Article Content

Jessica Ariatna Carreto Navarrete
Estanislao Antonio Calixto
Pedro Arredondo Ruiz
David Sandoval Sánchez
Josué Isaac Olarte García
Charit Nayelly Chang Cruz
Alfredo Bautista de la Cruz

Abstract

Fibrolamellar hepatocellular carcinoma is a primary hepatic malignancy, primarily affecting adolescents and young adults without underlying liver disease. We present the case of a 22-year-old male farmer who presents burning pain in the epigastrium with an intensity of 2/10 on the VAS scale, on palpation with the presence of a tumor in the right hypochondrium with ultrasound of the liver and bile ducts with evidence of liver mass in the segment VIII, in addition to exploratory laparoscopy with the discovery of multiple implants in 70% of the liver surface. In the histopathological analysis with morphological findings compatible with fibrolamellar carcinoma. In the laboratory with AST 356 UI/L, ALT 205 UI/L, GGT 930 U/L, LDH 343 UI/L AF 638 UI/L, for which treatment was started with atezolizumab 1200 mg and bevacizumab 1000 mg. Continuing to follow up. Fibrolamellar hepatocellular carcinoma is a variant of hepatocellular carcinoma, which usually presents with non-specific symptoms. The imaging approach is fundamental in the diagnosis, being the anatomopathological confirmation. Despite being low frequency tumors, they should be suspected in all young patients with a palpable mass in the liver.

Article Details

How to Cite
Carreto Navarrete, J. A., Antonio Calixto, E., Arredondo Ruiz, P. ., Sandoval Sánchez, D., Olarte García, J. I., Chang Cruz, C. N., & Bautista de la Cruz, A. . (2023). A Case of Fibrolamellar Hepatocellular Carcinoma at the High Specialty Hospital of Veracruz, Mexico . International Journal of Medical Science and Clinical Research Studies, 3(02), 209–211. https://doi.org/10.47191/ijmscrs/v3-i2-11
Section
Articles

References

I. Mayo SC, Mavros MN, Nathan H. Treatment and Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma; a National Perspective. J Am Coll Surg. 2014;218(2):196-205.

II. Petrick JL, Kelly SP, Altekruse SF. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. J Clin Oncol 2016;34: 1787–1794.

III. White DL, Thrift AP, Kanwal F. Incidence of Hepatocellular Carcinoma in all 50 United States, from 2000 Through 2012. Gastroenterology 2017;152: 812–820.e5.

IV. Serag HBE, Dávila JA. ¿Es el Carcinoma Fibrolamelar Diferente del Carcinoma Hepatocelular. Un estudio basado en la población de EE. UU. Hepatología 2004;39:798-803.

V. Eggert T, McGlynn KA, Duffy A. Carcinoma Hepatocelular Fibrolamelar en los EE. UU., 2000-2010: Un Informe Detallado sobre la Frecuencia, el Tratamiento y el Resultado basado en la Base de Datos de Vigilancia, Epidemiología y Resultados Finales. United European Gastroenterol J 2013;1: 351-7.

VI. Nasr JA, Villalobos LG, Nuncio J, Maldonaldo H, Bornstein-Quevedo L. Fibrolamellar Hepatocellular Carcinoma in Mexican Patients. Pathol Oncol Res. 2002;8: 133-7.

VII. Ramai D, Ofosu A, Lai JK, Gao ZH, Adler DG. Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study. Dig Dis Sci. 2020 Feb 12.

VIII. Ganeshan D, Szklaruk J, Kundra V, Kaseb V, Rashid A, Elsayes KM. Imaging Features of Fibrolamellar Hepatocellular Carcinoma. AJR Am J Roentgenol 2014; 202(3): 544-52

IX. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Fibrolamellar Hepatocellular Carcinoma in the USA, 2000-2010: A Detailed Report on Frequency, Treatment and Outcome Based on the Surveillance, Epidemiology, and End Results Database. United European Gastroenterol J. 2013;1: 351-7.

X. Ang CS, Kelley RK, Choti MA, Cosgrove DP, Chou JF, Klimstra D, Clinicopathologic characteristics and Survival Outcomes of Patients with Fibrolamellar Carcinoma: Data From the Fibrolamellar Carcinoma Consortium.

XI. Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM. Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular

XII. Carcinoma.Oncology. 2013;85(4):197.

XIII. Stipa F, Yoon SS, Liau KH, Fong Y. Outcome of Patients With Fibrolamellar Hepatocellular Carcinoma. Cancer. 2006; 106(6): 1331.

XIV. Tomasini MD, Wang Y, Karamafrooz A, Karamafrooz A, Li G, Beuming T, et al. Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma. Sci Rep 2018; 8(1):720.

Most read articles by the same author(s)

<< < 1 2